Search Results
Your search for ,foR matches 32457 pages
Showing 26351 - 26400Flaws in CNBSS Are Vast, Impact on Screening Recommendations Is Nil
The recent report from the Canadian National Breast Screening Study (CNBSS)—published in BMJ and reviewed in The ASCO Post, early release online—concluded that annual mammography in women aged 40 to 59 does not result in a reduction in mortality from breast cancer beyond that of physical...
No Mortality Benefit of Breast Cancer Mammography Screening in 25-Year Follow-up of Canadian National Breast Screening Study
As reported in BMJ by Anthony B. Miller, MD, Professor Emeritus at the Dalla Lana School of Public Health, University of Toronto, and colleagues, the 25-year follow-up of the Canadian National Breast Screening Study has shown no mortality benefit of annual mammography screening for breast cancer...
2014 Oncology Meetings
MARCH 31st Annual Miami Breast Cancer Conference®March 6-9 • Miami Beach, FloridaFor more information: www.gotoper.com/conferences/mbcc/meetings/31st-Annual-Miami-Breast-Cancer-Conference Hematology and Medical Oncology Board Review: Contemporary Practice from Memorial Sloan-Kettering Cancer...
APSHO: New Society for Advanced Practitioners
The Advanced Practitioner Society for Hematology and Oncology (APSHO) was launched during JADPRO Live. The Society is focused on meeting the unique educational and professional needs of this group of health-care professionals (nurse practioners, physician assistants, clinical nurse specialists,...
Leaders of ASCO, ASH, ASTRO, and NCCN Embrace Collaboration With Advanced Practitioners
Nearly 250 advanced practitioners assembled at the first annual JADPRO Live educational symposium in St. Petersburg, Florida, hosted by the Journal of the Advanced Practitioner in Oncology (JADPRO). Leaders from four prominent oncology organizations championed collaborative practice as not only...
Expert Point of View: Jennifer R. Brown, MD, PhD
Commenting on the CLL 11 trial in chronic lymphocytic leukemia (CLL), Jennifer R. Brown, MD, PhD, Director of the CLL Center at Dana-Farber Cancer Institute, Boston, said she agreed with first author Valentin Goede, MD, that in this study, replacing rituximab (Rituxan) with obinutuzumab (Gazyva) in ...
Encouraging Early Results With Novel Agents in CLL
Two novel agents have shown promising activity in chronic lymphocytic leukemia (CLL), including poor-risk patients: the Bcl-2 inhibitor ABT-199 and the small-molecule PI3K inhibitor IPI-145. Both drugs achieved excellent response rates in heavily pretreated relapsed/refractory patients including...
First-Line Obinutuzumab/Chlorambucil Improves Outcomes Over Rituximab/Chlorambucil in Older CLL Patients With Comorbidities
Obinutuzumab (Gazyva) plus chloramubucil outperformed rituximab (Rituxan) plus chlorambucil (Leukeran) as first-line therapy in older patients with chronic lymphocytic leukemia (CLL) and comorbidities in the large CLL 11 trial. Final results showed that obinutuzumab/chloramubucil improved overall...
FDA Approves Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration (FDA) has expanded the approved use of ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy. Ibrutinib, an oral Bruton’s tyrosine kinase inhibitor, was previously granted...
Expert Point of View: Jeffrey Miller, MD
Jeffrey Miller, MD, Professor of Medicine at the University of Minnesota and Deputy Director of the Masonic Cancer Clinic in Minneapolis, commented on the haploidentical hematopoietic stem cell transplantation studies presented at the American Society of Hematology meeting for The ASCO Post “The...
Haploidentical Stem Cell Transplantation Producing Good Outcomes, Expanding Transplant Pool
HLA-haploidentical hematopoietic stem cell transplantation can be performed safely, yield good outcomes, and greatly expand the number of patients with hematologic malignancies who can be treated with stem cell transplant, studies presented at the 2013 American Society of Hematology (ASH) Annual...
Expert Point of View: C. Kent Osborne, MD
At the San Antonio Breast Cancer Symposium, press briefing moderator C. Kent Osborne, MD, Director of the Dan Duncan Cancer Center at Baylor College of Medicine, Houston, predicted the findings of the study by Badwe et al could be practice-changing. “This is not to say that we shouldn’t perform...
In Stage IV Breast Cancer, the Primary May Not Need to Be Removed
Mastectomy is unnecessary in many women with stage IV breast cancer, according to a study from Indian investigators, reported at the 2013 San Antonio Breast Cancer Symposium.1 The study randomly assigned 350 patients with metastatic breast cancer to mastectomy, complete axillary dissection, plus...
Updated Information on Clinical Trials
Your patients can learn about clinical trials in a variety of ways at www.cancer.net/clinicaltrials. The articles available explain what clinical trials are, how they are used to learn more about cancer care, and how they are conducted. In addition, your patients can read a new article explaining...
Cancer.Net Expands Its Social Media Presence With Launch of Blog
In an effort to continue to bring patients and those who care about and for them the most timely, comprehensive cancer information, ASCO’s patient education website, Cancer.Net, has added a new interactive resource—the Cancer.Net Blog (www.cancer.net/blog). “We decided that a blog made sense for...
Cancer Progress in Jeopardy: Stories From the Front Lines
ASCO is exploring what is happening on the front lines in the laboratory and the clinic due to the shrinking federal funding for cancer research and clinical trials with a series of stories about oncologists. The series is posted on ASCO.org (www.asco.org/nihfunding). In the first article, Robert...
ASCO to Release Report on the State of Cancer Care in America
ASCO is committed to ensuring that Americans have access to high-quality, high-value cancer prevention and treatment services—and that all patients benefit fully from our nation’s investments in cancer research. In mid-March, the Society will be releasing The State of Cancer Care in America: 2014,...
Connecting to Conquer Cancer
Do you share our passion to conquer cancer? Connect with the Conquer Cancer Foundation online to receive up-to-the-minute news and events, researcher spotlights, videos, and updates on progress against cancer worldwide. Visit our website to learn more about our mission and the programs we support:...
Amplifying the Signal: Foundation Donor Takes His Advocacy Into the Twittersphere
Michael A. Thompson, MD, PhD, a Medical Oncologist for Aurora Cancer Care and the Medical Director of Early Cancer Research at Aurora Health Care in Wisconsin, has become something of an expert on the Conquer Cancer Foundation. It began in 2006, when he received a Conquer Cancer Foundation of ASCO...
Expert Point of View: Carlos L. Arteaga, MD
Commenting on the results of the HOPE Study presented at the 2013 San Antonio Breast Cancer Symposium, Carlos L. Arteaga, MD, said, “We all know that this is the right thing to do. This important study provides us with new guidelines and a structure so that patients find it easier to follow the...
Exercise Program Reduces Aromatase Inhibitor–Associated Joint Pain
Amid studies of novel targeted therapies, genetic analyses of tumors, and new ways to approach the treatment of breast cancer, a low-tech study presented at the 2013 San Antonio Breast Cancer Symposium found that a yearlong exercise program reduced joint pain associated with aromatase inhibitors in ...
Innovative I-SPY 2 Trial Yields First Results in Triple-Negative Breast Cancer
An innovative approach to streamlining the testing of novel agents in breast cancer has yielded some of its first results, which were reported at the 2013 San Antonio Breast Cancer Symposium.1 Adaptive Trial Design The veliparib/carboplatin plus standard neoadjuvant therapy regimen is currently...
Expert Point of View: Debu Tripathy, MD
Debu Tripathy, MD, Professor of Medicine, Co-Leader of the Women’s Cancer Program, and the Priscilla and Art Ulene Chair in Women’s Cancer at the University of Southern California Norris Cancer Center, Los Angeles, commented on the APT study for The ASCO Post. “In treating early-stage HER2-positive ...
HER2-Positive Breast Cancer Patients With Small Tumors Benefit From Low-Toxicity Regimen
There may be a benefit for treating small HER2-positive tumors—a breast cancer subset for whom treatment recommendations have not been established but for whom there is still risk of recurrence—and this can be done with little toxicity, according to a multicenter study presented at the 2013 San...
ASCO Applauds CVS Caremark’s Move to Stop Selling Tobacco
CVS Caremark recently announced that it will stop selling cigarettes and other tobacco products at its more than 7,600 CVS/pharmacy stores across the United States by October 1, 2014, making CVS/pharmacy the first national pharmacy chain to take this step in support of the health and well-being of...
GI Symposium Presentations Include Important Updates in Treatment and Prognosis of Pancreatic and Colorectal Cancers
More than 650 studies were presented at the 2014 Gastrointestinal Cancers Symposium, which attracted a multidisciplinary group of more than 3,500 medical, surgical, and radiation oncologists and gastroenterologists. The following briefs highlight a handful of noteworthy studies from the meeting....
ASCO Supports Reinforcing FDA Capacity to Monitor Nation’s Drug Supply
“The GAO report identifies production lapses due to quality problems and constrained manufacturing capacity as being the central causes of the widespread incidence and persistence of drug shortages. “The report also emphasizes that the FDA has made significant progress in preventing shortages by ...
U.S. Government Accountability Office Issues Report on Drug Shortages
The U.S. Government Accountability Office (GAO) recently issued a report evaluating drug shortages and the associated public health threats, including prolonged duration of a disease, permanent injury, and death.1 This report follows a recommendation by GAO in 2011 that the U.S. Food and Drug...
Capecitabine Acceptable in Neoadjuvant Rectal Cancer Setting
As neoadjuvant therapy for rectal cancer, infusional fluorouracil (5-FU) and oral capecitabine achieve similar outcomes, and the addition of oxaliplatin confers no additional benefit, according to the mature results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) R-04 trial,...
Expert Point of View: Josep M. Llovet, MD
Josep M. Llovet, MD, Professor of Medicine at Mount Sinai Hospital, New York, commented on the findings reported by Faivre et al for The ASCO Post. “This is the first time a TGF-β inhibitor has been clinically tested in hepatocellular carcinoma, and the drug has a good safety profile. But this is a ...
Biomarker-Defined Subgroup Benefits From Novel Approach to Advanced Hepatocellular Carcinoma
Promising efficacy in advanced hepatocellular carcinoma patients was reported for a novel transforming growth factor–beta receptor type 1 (TGF-β1) kinase inhibitor, LY2157299 monohydrate, at the 2014 Gastrointestinal Cancers Symposium in San Francisco.1 In particular, patients with moderate to...
Expert Point of View: Melanie B. Thomas, MD
Melanie B. Thomas, MD, Associate Director of Clinical Investigations and the Grace E. DeWolff Chair of Medical Oncology at the Medical University of South Carolina in Charleston, commented on the findings by Martin et al for The ASCO Post. “I think this study is exciting,” she said. “They were...
Irinotecan Drug-Eluting Beads Improve Outcomes in Colorectal Cancer Patients With Liver Metastases
Irinotecan drug-eluting beads (DEBIRI) given simultaneously with FOLFOX (leucovorin, fluorouracil, oxaliplatin) and bevacizumab (Avastin) in patients with unresectable colorectal liver metastasis improved response rates, increased resectability, and prolonged hepatic progression–free survival in a...
Expert Point of View: Michael J. Morris, MD, and Maha H. Hussain, MD, FACP, FASCO
Commenting on the ALSYMPCA follow-up study presented at the Genitourinary Cancers Symposium, Michael J. Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, New York, said that radium-223 was a very effective and safe drug, but its actual target and mechanism of action are...
Long-Term Safety Data on Radium-223 in Prostate Cancer Reassuring
Long-term follow-up of the ALSYMPCA trial showed that radium Ra 223 dichloride (Xofigo) is extremely safe and active in men with castration-resistant prostate cancer and bone metastases. A snapshot of safety data from about 1.5 years after patients’ final radium-223 injection shows minimal...
Expert Point of View: Daniel J. Canter, MD
“We have a lot of options for first-line therapy [in renal cell carcinoma] these days. The question is, what do we do with first-line failures?” said Daniel J. Canter, MD, formal discussant of the SWITCH trial at the Genitourinary Cancers Symposium. Dr. Canter is Vice Chairman of the Urologic...
Sequencing Sorafenib and Sunitinib in Either Order Does Not Affect Survival in Metastatic Renal Cell Carcinoma
The explosion of new therapies for metastatic renal cell carcinoma is a welcome advance, but studies have not yet defined optimal sequencing of the newer therapies. According to the phase III SWITCH trial, it matters little whether therapy for metastatic renal cell carcinoma begins with sorafenib...
Expert Point of View: Daniel J. Canter, MD
“Cytoreductive nephrectomy is routinely used in metastatic renal cell carcinoma, but its use is not as firmly established in the targeted therapy era. And its use is not without risk,” said formal discussant of the International Metastatatic Renal Cell Carcinoma Database Consortium (IMDC) trial,...
Cytoreductive Nephrectomy Improves Survival in Metastatic Renal Cell Carcinoma Patients With Longer Life Expectancy
Prior to the advent of targeted therapy, cytoreductive nephrectomy was associated with a 6-month improvement in overall survival in patients with metastatic renal cell carcinoma. With new and better targeted therapies for the disease, the appropriate use of cytoreductive nephrectomy has been...
Congress Agrees on Repeal of Sustainable Growth Rate
The U.S. Congress recently did something rarely seen on Capitol Hill: Leaders from both sides of the aisle agreed on a piece of legislation. On February 6, 2014, the House Energy and Commerce and Ways and Means Committees and the Senate Finance Committee announced its agreement on a bill—the SGR...
The Future of Biomedical Research
In January, Congress approved a $1 trillion appropriations bill for the rest of fiscal year 2014. While the new bill includes $29.9 billion for the National Institutes of Health (NIH)—$1 billion above FY2013 levels after sequestration—including $4.9 billion for the National Cancer Institute (NCI),...
Expert Point of View: Charles Ryan, MD
Charles Ryan, MD, moderator of the press conference at the Genitourinary Cancers Symposium where the PREVAIL trial data were discussed, emphasized that this study breaks new ground for enzalutamide (Xtandi) in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. “The...
PREVAIL Trial Shows Enzalutamide to Be a Promising Option for Metastatic Castration-Resistant Prostate Cancer
Encouraging results of the large phase III PREVAIL trial represent another positive milestone for men with metastatic castration-resistant prostate cancer. Enzalutamide (Xtandi) improved overall survival by 29% and reduced the risk of radiographic progression of disease by 81% in men who had not...
After Next-Generation Sequencing: Guiding Patients to the Right Treatment
In the near future, community oncologists will be tasked with helping patients interpret the results of next-generation sequencing of their tumors. Specifically, we will help patients choose an academic center with a phase I targeted therapy program that is a plausible fit for their disease....
The Author Replies
I read with interest the note from Jeff Boyd, PhD, Senior Vice-President for Molecular Medicine at Fox Chase Cancer Center, calling into question my recent commentary about the high costs of partly validated testing in the domain of molecular medicine. One of the oldest tricks in the book is to...
Cancer Genes and Molecular Medicine: More Education Needed
I read with interest and concern the Perspective piece, “Cancer Genes, Promiscuity, and the National Debt,” which appeared on page 1 of the February 1st issue of The ASCO Post. The underlying premise of this wide-ranging and provocative article would appear to be that in a rush to implement...
Task Force Recommends Against Beta-Carotene or Vitamin E Supplements for Primary Cancer Prevention
The U.S. Preventive Services Task Force (USPSTF) recommends against the use of beta-carotene or vitamin E supplementation for the primary prevention of cancer or cardiovascular disease, according to an updated recommendation statement published in the Annals of Internal Medicine. “The USPSTF found...
‘Epidemic of Diagnosis’ of Thyroid Cancer Is Most Acute for Women
The epidemiology of the increased incidence of thyroid cancer, which has nearly tripled since 1975, “suggests that it is not an epidemic of disease but rather an epidemic of diagnosis,” Louise Davies, MD, MS, and H. Gilbert Welch, MD, MPH, concluded after analyzing trends in patients diagnosed with ...
Dietary Lycopene Linked to Reduced Risk of Lethal Prostate Cancer, Less Tumor Angiogenesis
“Dietary intake of lycopene was associated with reduced risk of lethal prostate cancer and with a lesser degree of angiogenesis in the tumor,” Ke Zu, MD, of Harvard School of Public Health, Boston, and colleagues concluded after reviewing dietary information and total and lethal prostate cancer...
Aspirin Associated With Reduced Risk of Ovarian Cancer, Especially in Low Daily Doses
“Aspirin use was associated with a reduced risk of ovarian cancer, especially among daily users of low-dose aspirin,” according to an analysis of pooled individual data from the Ovarian Cancer Association Consortium. Analyzing data from 12 population-based case-control studies of ovarian cancer,...
